Printer Friendly

IVAX ANNOUNCES RECORD EARNINGS

 IVAX ANNOUNCES RECORD EARNINGS
 MIAMI, Aug. 6 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) today


announced its results of operations for the three and six months ended June 30, 1992.
 The results of operations and a summary balance sheet are detailed below:
 IVAX CORPORATION
 Results of Operations
 (In thousands, except per share data)
 Three Months Ended June 30,
 1992 1991
 Revenues $ 93,847 $ 46,128
 Net income before income taxes $ 6,121 $ 3,889
 Net income $ 5,142 $ 3,825
 Earnings per share $ .08 $ .06
 Average shares outstanding 67,387 60,974
 Six Months Ended June 30,
 1992 1991
 Revenues $192,003 $ 94,435
 Net income before income taxes $ 10,395 $ 7,817
 Net income $ 8,879 $ 6,782
 Earnings per share $ .13 $ .11
 Average shares outstanding 67,589 59,566
 Balance Sheet
 (In thousands)
 Assets
 June 30, Dec. 31,
 1992 1991
 Current assets $249,440 $274,010
 Property, plant and
 equipment, net 51,820 48,278
 Other assets 152,402 139,524
 Total assets $453,662 $461,812
 Liabilities and Stockholders' Equity
 June 30, Dec. 31,
 1992 1991
 Current liabilities $105,522 $126,882
 Other long-term debt 134,465 136,105
 Other long-term liabilities 1,725 1,577
 Shareholders' equity 211,950 197,248
 Total liabilities and
 stockholders' equity $453,662 $461,812
 The company noted that all 1991 financial information has been restated to reflect the pooling of interest mergers of Willen Drug Company, DVM Pharmaceuticals Inc. and Waverley Pharmaceutical Limited.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. Inc. IVAX' principal subsidiaries include Baker Norton Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off- patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off- patent prescription and over the counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; DVM Pharmaceuticals Inc., a veterinary products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 8/6/92
 /CONTACT: F. E. Baxter, senior vice president-finance and chief financial officer of IVAX Corporation, 305-590-2318/
 (IVX) CO: IVAX Corporation; Flori Roberts, Inc. ST: Florida IN: MTC SU: ERN


AW-JB -- FL001 -- 7393 08/06/92 08:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 6, 1992
Words:408
Previous Article:MAC FRUGAL'S BARGAINS - CLOSE-OUTS CONFIRMS STOCK BUY BACK
Next Article:UNITED RETAIL GROUP ANNOUNCES JULY 1992 SALES INCREASE OF 27 PERCENT
Topics:


Related Articles
IVAX ANNOUNCES RECORD EARNINGS
IVAX ANNOUNCES RECORD EARNINGS
IVAX AND TRINITY CAPITAL ENTERPRISE ANNOUNCE EXECUTION OF AGREEMENT
IVAX ANNOUNCES RECORD EARNINGS
IVAX ANNOUNCES A 233 PERCENT EARNINGS INCREASE
IVAX ANNOUNCES A 253 PERCENT EARNINGS INCREASE AND DECLARES A CASH DIVIDEND
IVAX COMMENTS ON LAWSUIT FILED BY JAMES SWEENEY
IVAX CORPORATION ESTABLISHES $425 MILLION CREDIT FACILITY
IVAX CORPORATION PROVIDES OUTLOOK FOR SECOND QUARTER EARNINGS
IVAX ANNOUNCES 1996 SECOND QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters